H.I.G. Capital News

Intact Vascular Adds Howard Rosen to Its Executive Management Team as VP Marketing and Business Development

WAYNE, PA - May 1, 2017 - Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced that Howard Rosen has joined its executive management team as Vice President of Marketing and Business Development. In this position, Mr. Rosen will lead the company’s efforts to prepare for commercialization of its Tack Endovascular System® for the repair of dissections following peripheral artery angioplasty.

“Howard brings deep experience in both upstream and downstream marketing, as well as first-hand knowledge of the peripheral vascular marketplace and our customers,” said Bruce J. Shook, Intact Vascular’s President and CEO. “Howard is a welcome addition to our team as we move through the Pre-Market Approval (PMA) application process and toward market introduction of our products,” Shook continued.

Prior to joining Intact Vascular, Mr. Rosen’s career included twenty-one years at Boston Scientific Corporation (NYSE: BSX), where he began his career as a sales representative and rose through the marketing ranks to hold positions of increasing responsibility in the peripheral vascular interventions and cardiovascular businesses. Mr. Rosen most recently served as Vice President of the Cell Processing Franchise at the Haemonetics Corporation (NYSE: HAE).

“Intact Vascular has created a novel solution to the widespread problem of dissections following angioplasty, and the company has made a significant investment in clinical research. I am excited to build on that strong foundation and bring this important technology to clinicians and their patients,” said Mr. Rosen.

Intact Vascular is sponsoring three clinical trials to evaluate its Tack Endovascular System: TOBA II, TOBA II BTK and TOBA III. TOBA II is investigating the combination of the Tack® device, with both plain and drug-coated balloon angioplasty in the arteries above the knee. TOBA II BTK is investigating the combination of the Tack device with plain balloon angioplasty in the arteries below the knee. TOBA III is currently underway in Europe and is investigating the combination of the Tack Endovascular System with drug-coated balloon angioplasty. Visit http://www.intactvascular.com/actively-enrolling for more information on Intact Vascular’s robust clinical development program in the endovascular treatment of peripheral arterial disease.

About Intact Vascular
Intact Vascular is a privately held medical device company that develops minimally invasive peripheral vascular products. The Tack Endovascular System is designed to optimize percutaneous balloon angioplasty results in the treatment of peripheral arterial disease. Visit www.intactvascular.com for more information.

This press release contains “forward-looking statements” concerning the development of Intact Vascular's products, the potential benefits and attributes of such products, and the company’s expectations regarding its prospects. Forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of the date of this press release. Actual results may vary. Intact Vascular undertakes no obligation to update any forward-looking statements for any reason.

Contacts
Intact Vascular, Inc.
Andrea Dunkle, 1-484-253-1048
adunkle@intactvascular.com

Tack Endovascular System® and Tack® are trademarks of Intact Vascular, Inc.
IN.PACT and Admiral are trademarks of Medtronic, Inc.
Lutonix is a trademark of C.R. BARD, Inc.

"CAUTION: Investigational device. Limited by Federal (United States) law to investigational use."
The Tack Endovascular System® is CE Mark Authorized under EC Directive 93/42/EEC.
Not available for sale or use in the United States